               SEQUENCE LISTING

<110> AZIENDA OSPEDALIERA UNIVERSITARIA SENESE
      PAPINI, ANNA MARIA
      ROVERO, PAOLO
      NUTI, FRANCESCA
      REAL-FERNANDEZ, FELICIANA
      SABATINO, GIUSEPPINA
      TIBERI, CATERINA

<120> Novel glycosilated peptides

<130> 11848+12029PTWO

<150> FI2012A000107
<151> 2012-06-05
<150> FI2012A000164
<151> 2012-08-07

<160> 19

<170> BiSSAP 1.2

<210> 1
<211> 11
<212> PRT
<213> Artificial Sequence

<220> 
<221> MOD_RES
<222> 1..1
<223> ACETYLATION

<220> 
<221> SITE
<222> 1..1
<223> absent or any amino acid preferably selected in the group
      consisitng of Ala, Arg, bAla, Gly, Glu, His, Phe, Ser, Thr

<220> 
<221> REPEAT
<222> 1..8
<223> sequence repeated at branched positions 9 and 10

<220> 
<223> synthetic branched tetrameric glycopeptide

<220> 
<221> SITE
<222> 2..2
<223> absent or any amino acid preferably selected in the group
      consisitng of Ala, Arg, bAla, Gly, Glu, His, Phe, Ser, Thr

<220> 
<221> SITE
<222> 3..3
<223> absent or any amino acid preferably selected in the group
      consisitng of Ala, Arg, bAla, Gly, Glu, His, Phe, Ser, Thr

<220> 
<221> CARBOHYD
<222> 4..4
<223> monosaccharide or disaccharide

<220> 
<221> SITE
<222> 5..5
<223> absent or any amino acid preferably selected in the group
      consisitng of Ala, Arg, bAla, Gly, Glu, His, Phe, Ser, Thr

<220> 
<221> SITE
<222> 6..6
<223> absent or any amino acid preferably selected in the group
      consisitng of Ala, Arg, bAla, Gly, Glu, His, Phe, Ser, Thr

<220> 
<221> SITE
<222> 7..7
<223> absent or any amino acid preferably selected in the group
      consisitng of Ala, Arg, bAla, Gly, Glu, His, Phe, Ser, Thr

<220> 
<221> SITE
<222> 8..8
<223> selected in the group consisting of Gly, bAla;
      -HN-(CH2)p-(O-CH2-CH2)m-(CH2)k-HN-CO-(CH2)j-CO- with p = 1-3 , k
      = 1-3, j = 1-3 and m = 1-5; or -HN-(CH2-CH2-O)q-(CH2)r-CO- con q
      = 1-10 ed r = 1,2

<220> 
<221> SITE
<222> 9..9
<223> amino acid (natural or non natural) having at least 2 amino
      functions

<220> 
<221> SITE
<222> 9..9
<223> branched position bearing: (repeat residues 1-8)-

<220> 
<221> SITE
<222> 10..10
<223> amino acid (natural or non natural) having at least 2 amino
      functions

<220> 
<221> SITE
<222> 10..10
<223> branched position bearing: (repeat residues 1-8)2-(an amino acid
      having at least two amino functions)-

<220> 
<221> SITE
<222> 11..11
<223> C-terminal amino acid, with free -COOH, preferably selected in
      the group consisitng of Ala, Arg, bAla, Gly, Glu, His, Phe, Ser,
      Thr

<400> 1
Xaa Xaa Xaa Asn Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1               5                   10      

<210> 2
<211> 11
<212> PRT
<213> Artificial Sequence

<220> 
<221> MOD_RES
<222> 1..1
<223> ACETYLATION

<220> 
<221> SITE
<222> 1..1
<223> His, Gly, Arg, Glu, Ser, Trh or absent

<220> 
<221> REPEAT
<222> 1..8
<223> sequence repeated at branched positions 9 and 10

<220> 
<223> synthetic branched tetrameric glycopeptide

<220> 
<221> SITE
<222> 2..2
<223> His, Gly, Arg, Glu, Ser, Trh or absent

<220> 
<221> SITE
<222> 3..3
<223> His, Gly, Arg, Glu, Ser, Trh or absent

<220> 
<221> CARBOHYD
<222> 4..4
<223> selected in the group consisitng of Glc, GlcNAc,
      beta-D-Glcp-(1-4)-D-Glc

<220> 
<221> SITE
<222> 5..5
<223> His, Gly, Arg, Glu, Ser, Trh or absent

<220> 
<221> SITE
<222> 6..6
<223> His, Gly, Arg, Glu, Ser, Trh or absent

<220> 
<221> SITE
<222> 7..7
<223> His, Gly, Arg, Glu, Ser, Trh or absent

<220> 
<221> SITE
<222> 8..8
<223> bAla

<220> 
<221> SITE
<222> 9..9
<223> branched position bearing: (repeat residues 1-8)-

<220> 
<221> SITE
<222> 10..10
<223> branched position bearing (repeat residues 1-8)2-Lys-

<220> 
<221> MOD_RES
<222> 11..11
<223> bAla

<400> 2
Xaa Xaa Xaa Asn Xaa Xaa Xaa Xaa Lys Lys Xaa 
1               5                   10      

<210> 3
<211> 11
<212> PRT
<213> Artificial Sequence

<220> 
<221> MOD_RES
<222> 1..1
<223> ACETYLATION

<220> 
<221> SITE
<222> 1..1
<223> His, Gly, Arg, Glu, Ser, Thr or absent

<220> 
<221> REPEAT
<222> 1..8
<223> sequence repeated at branched positions 9 and 10

<220> 
<223> synthetic branched tetrameric glycopeptide

<220> 
<221> SITE
<222> 2..2
<223> His, Gly, Arg, Glu, Ser, Thr or absent

<220> 
<221> SITE
<222> 3..3
<223> His, Gly, Arg, Glu, Ser, Thr or absent

<220> 
<221> CARBOHYD
<222> 4..4
<223> selected in the group consisitng of Glc, GlcNAc,
      beta-D-Glcp-(1-4)-D-Glc

<220> 
<221> SITE
<222> 5..5
<223> His, Gly, Arg, Glu, Ser, Thr or absent

<220> 
<221> SITE
<222> 6..6
<223> His, Gly, Arg, Glu, Ser, Thr or absent

<220> 
<221> SITE
<222> 7..7
<223> His, Gly, Arg, Glu, Ser, Thr or absent

<220> 
<221> SITE
<222> 8..8
<223> -NH-(CH2-CH2-O)n-(CH2)p-CO- wherein n=1-5, p=1-3

<220> 
<221> SITE
<222> 9..9
<223> branched position bearing: (repeat residues 1-8)-

<220> 
<221> SITE
<222> 10..10
<223> branched position bearing: (repeat residues 1-8)2-Lys-

<220> 
<221> MOD_RES
<222> 11..11
<223> bAla

<400> 3
Xaa Xaa Xaa Asn Xaa Xaa Xaa Xaa Lys Lys Xaa 
1               5                   10      

<210> 4
<211> 11
<212> PRT
<213> Artificial Sequence

<220> 
<221> MOD_RES
<222> 1..1
<223> ACETYLATION

<220> 
<221> SITE
<222> 1..1
<223> His, Gly, Arg, Glu, Ser, Thr or absent

<220> 
<221> REPEAT
<222> 1..8
<223> sequence repeated at branched positions 9 and 10

<220> 
<223> synthetic branched tetrameric glycopeptide

<220> 
<221> SITE
<222> 2..2
<223> His, Gly, Arg, Glu, Ser, Thr or absent

<220> 
<221> SITE
<222> 3..3
<223> His, Gly, Arg, Glu, Ser, Thr or absent

<220> 
<221> CARBOHYD
<222> 4..4
<223> selected in the group consisitng of Glc, GlcNAc,
      beta-D-Glcp-(1-4)-D-Glc

<220> 
<221> SITE
<222> 5..5
<223> His, Gly, Arg, Glu, Ser, Thr or absent

<220> 
<221> SITE
<222> 6..6
<223> His, Gly, Arg, Glu, Ser, Thr or absent

<220> 
<221> SITE
<222> 7..7
<223> His, Gly, Arg, Glu, Ser, Thr or absent

<220> 
<221> SITE
<222> 8..8
<223> -NH-(CH2)p-(O-CH2-CH2)n-CH2-NH-CO-(CH2)q-CO- wherein n=1-5,
      p=1-3, q=1-3

<220> 
<221> SITE
<222> 9..9
<223> branched position bearing: (repeat residue 1-8)-

<220> 
<221> SITE
<222> 10..10
<223> branched position bearing: (repeat residue 1-8)2-Lys-

<220> 
<221> SITE
<222> 11..11
<223> bAla

<400> 4
Xaa Xaa Xaa Asn Xaa Xaa Xaa Xaa Lys Lys Xaa 
1               5                   10      

<210> 5
<211> 26
<212> PRT
<213> Artificial Sequence

<220> 
<221> SITE
<222> 1..5
<223> residues may be absent, if present they form a group of 2-5
      aminoacids

<220> 
<223> synthetic sequence

<220> 
<221> SITE
<222> 6..6
<223> is absent or is a trifunctional aminoacid capable of forming a
      lactamic bridge, by means of its side chain, with residue 11

<220> 
<221> SITE
<222> 7..7
<223> selected in the group consisting of Glu, Asp, Lys, Arg, Orn and
      Dap

<220> 
<221> CARBOHYD
<222> 8
<223> selected in the group consisitng of Glc, GlcNAc,
      beta-D-Glcp-(1-4)-D-Glc

<220> 
<221> SITE
<222> 9..9
<223> Pro or Gly

<220> 
<221> SITE
<222> 10..10
<223> selected in the group consisitng of Ala, Val, Ile and His

<220> 
<221> SITE
<222> 11..11
<223> is absent or is a trifunctional aminoacid capable of forming a
      lactamic bridge, by means of its side chain, with residue 6

<220> 
<221> SITE
<222> 12..26
<223> residues may present or not in order to form a group of 5-15
      amino acids

<400> 5
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1               5                   10                  15      
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
            20                  25      

<210> 6
<211> 21
<212> PRT
<213> Artificial Sequence

<220> 
<223> glycopeptide

<220> 
<221> CARBOHYD
<222> 7..7
<223> the carbohydrate is beta-D-glucopyranosyl

<300> 
<302> GLYCOPEPTIDES, THEIR PREPARATION AND USE IN THE DIAGNOSIS OR
      THERAPEUTIC TREATMENT OF MULTIPLE SCLEROSIS
<310> WO03/000733
<311> 2002-06-19
<312> 2003-01-03
<313> (1)..(21)

<400> 6
Thr Pro Arg Val Glu Arg Asn Gly His Ser Val Phe Leu Ala Pro Tyr 
1               5                   10                  15      
Gly Trp Met Val Lys 
            20      

<210> 7
<211> 21
<212> PRT
<213> Artificial Sequence

<220> 
<223> GLYCOPEPTIDE

<220> 
<221> SITE
<222> 5..5
<223> Xaa is diamino propanoic acid

<220> 
<221> CARBOHYD
<222> 7..7
<223> the carbohydrate is beta-D-glucopyranosyl

<300> 
<302> GLYCOPEPTIDES, THEIR PREPARATION AND USE IN THE DIAGNOSIS OR
      THERAPEUTIC TREATMENT OF MULTIPLE SCLEROSIS
<310> WO03/000733
<311> 2002-06-19
<312> 2003-01-03
<313> (1)..(21)

<400> 7
Thr Pro Arg Val Xaa Arg Asn Gly His Asp Val Phe Leu Ala Pro Tyr 
1               5                   10                  15      
Gly Trp Met Val Lys 
            20      

<210> 8
<211> 21
<212> PRT
<213> Artificial Sequence

<220> 
<223> glycopeptide

<220> 
<221> CARBOHYD
<222> 7..7
<223> the carbohydrate is beta-D-glucopyranosyl

<220> 
<221> SITE
<222> 10..10
<223> Xaa is Orn

<300> 
<302> GLYCOPEPTIDES, THEIR PREPARATION AND USE IN THE DIAGNOSIS OR
      THERAPEUTIC TREATMENT OF MULTIPLE SCLEROSIS
<310> WO03/000733
<311> 2002-06-19
<312> 2003-01-03
<313> (1)..(21)

<400> 8
Thr Pro Arg Val Asp Arg Asn Gly His Xaa Val Phe Leu Ala Pro Tyr 
1               5                   10                  15      
Gly Trp Met Val Lys 
            20      

<210> 9
<211> 13
<212> PRT
<213> Artificial Sequence

<220> 
<223> glycopeptide

<220> 
<221> CARBOHYD
<222> 6..6
<223> the carbohydrate is beta-D-glucopyranosyl

<300> 
<302> GLYCOPEPTIDES, THEIR PREPARATION AND USE IN THE DIAGNOSIS OR
      THERAPEUTIC TREATMENT OF MULTIPLE SCLEROSIS
<310> WO03/000733
<311> 2002-06-19
<312> 2003-01-03
<313> (1)..(13)

<400> 9
Ala Lys Thr Ala Lys Asn Gly His Val Glu Ala Ser Gly 
1               5                   10              

<210> 10
<211> 17
<212> PRT
<213> Artificial Sequence

<220> 
<223> glycopeptide

<220> 
<221> CARBOHYD
<222> 2..2
<223> the carbohydrate is beta-D-glucopyranosyl

<300> 
<302> GLYCOPEPTIDES, THEIR PREPARATION AND USE IN THE DIAGNOSIS OR
      THERAPEUTIC TREATMENT OF MULTIPLE SCLEROSIS
<310> WO30/000733
<311> 2002-06-19
<312> 2003-01-03
<313> (1)..(17)

<400> 10
Glu Asn Pro Val Val His Phe Phe Lys Asn Ile Val Thr Pro Arg Thr 
1               5                   10                  15      
Pro 
    

<210> 11
<211> 11
<212> PRT
<213> Artificial Sequence

<220> 
<223> glycopeptide

<220> 
<221> CARBOHYD
<222> 2..2
<223> the carbohydrate is beta-D-glucopyranosyl

<300> 
<302> GLYCOPEPTIDES, THEIR PREPARATION AND USE IN THE DIAGNOSIS OR
      THERAPEUTIC TREATMENT OF MULTIPLE SCLEROSIS
<310> WO03/000733
<311> 2002-06-19
<312> 2003-01-03
<313> (1)..(11)

<400> 11
Asp Asn Pro Val Glu Ala Phe Lys Gly Ile Ser 
1               5                   10      

<210> 12
<211> 22
<212> PRT
<213> Artificial Sequence

<220> 
<223> glycopeptide

<220> 
<221> CARBOHYD
<222> 7..7
<223> the carbohydrate is beta-D-glucopyranosyl

<220> 
<221> SITE
<222> 11..11
<223> Xaa is 7-aminoheptanoic acid

<300> 
<302> GLYCOPEPTIDES, THEIR PREPARATION AND USE IN THE DIAGNOSIS OR
      THERAPEUTIC TREATMENT OF MULTIPLE SCLEROSIS
<310> WO03/000733
<311> 2002-06-19
<312> 2003-01-03
<313> (1)..(22)

<400> 12
Thr Pro Arg Val Glu Arg Asn Gly His Ser Xaa Val Phe Leu Ala Pro 
1               5                   10                  15      
Tyr Gly Trp Met Val Lys 
            20          

<210> 13
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> glycopeptide

<220> 
<221> CARBOHYD
<222> 2..2
<223> the carbohydrate is beta-D-glucopyranosyl

<220> 
<221> SITE
<222> 13..15
<223> Xaa is beta-Ala

<300> 
<302> GLYCOPEPTIDES, THEIR PREPARATION AND USE IN THE DIAGNOSIS OR
      THERAPEUTIC TREATMENT OF MULTIPLE SCLEROSIS
<310> WO03/000733
<311> 2002-06-19
<312> 2003-01-03
<313> (1)..(15)

<400> 13
Asp Asn Pro Val Val His Phe Phe Lys Asn Ile Val Xaa Xaa Xaa 
1               5                   10                  15  

<210> 14
<211> 5
<212> PRT
<213> Artificial Sequence

<220> 
<221> MOD_RES
<222> 1..1
<223> ACETYLATION

<220> 
<221> CARBOHYD
<222> 1..1
<223> Glc

<220> 
<221> REPEAT
<222> 1..2
<223> sequence repeated at branched position 3 and 4

<220> 
<223> synthetic branched tetrameric glycopeptide

<220> 
<221> SITE
<222> 2..2
<223> -NH-(CH2)3(O-CH2-CH2)3-CH2-NH-CO-(CH2)2-CO-

<220> 
<221> SITE
<222> 3..3
<223> branched position bearing: (repeat residues 1-2)-

<220> 
<221> SITE
<222> 4..4
<223> branched position bearing: (repeat residues 1-2)2-Lys-

<220> 
<221> SITE
<222> 5..5
<223> bAla

<400> 14
Asn Xaa Lys Lys Xaa 
1               5   

<210> 15
<211> 7
<212> PRT
<213> Artificial Sequence

<220> 
<221> MOD_RES
<222> 1..1
<223> ACETYLATION

<220> 
<221> CARBOHYD
<222> 1..1
<223> Glc

<220> 
<221> REPEAT
<222> 1..4
<223> sequence repeated at branched positions 5 and 6

<220> 
<223> synthetic branched tetrameric glycopeptide

<220> 
<221> SITE
<222> 4..4
<223> -NH-(CH2)3(O-CH2-CH2)3-CH2-NH-CO-(CH2)2-CO-

<220> 
<221> SITE
<222> 5..5
<223> branched position bearing: (repeat residues 1-4)-

<220> 
<221> SITE
<222> 6..6
<223> branched position bearing: (repeat residues 1-4)2-Lys-

<220> 
<221> SITE
<222> 7..7
<223> bAla

<400> 15
Asn His Thr Xaa Lys Lys Xaa 
1               5           

<210> 16
<211> 9
<212> PRT
<213> Artificial Sequence

<220> 
<221> MOD_RES
<222> 1..1
<223> ACETYLATION

<220> 
<221> REPEAT
<222> 1..6
<223> sequence repeated at branched positions 7 and 8

<220> 
<223> synthetic branched tetrameric glycopeptide

<220> 
<221> CARBOHYD
<222> 3..3
<223> Glc

<220> 
<221> SITE
<222> 6..6
<223> -NH-(CH2)3(O-CH2-CH2)3-CH2-NH-CO-(CH2)2-CO-

<220> 
<221> SITE
<222> 7..7
<223> branched position bearing: (repeat residues 1-6)-

<220> 
<221> SITE
<222> 8..8
<223> branched position bearing: (repeat residues 1-6)2-Lys-

<220> 
<221> SITE
<222> 9..9
<223> bAla

<400> 16
Glu Arg Asn Gly His Xaa Lys Lys Xaa 
1               5                   

<210> 17
<211> 9
<212> PRT
<213> Artificial Sequence

<220> 
<221> MOD_RES
<222> 1..1
<223> ACETYLATION

<220> 
<221> REPEAT
<222> 1..6
<223> sequence repeated at branched positions 7 and 8

<220> 
<223> synthetic branched tetrameric glycopeptide

<220> 
<221> CARBOHYD
<222> 3..3
<223> Glc

<220> 
<221> SITE
<222> 6..6
<223> -NH-(CH2-CH2-O)2-CH2-CO-

<220> 
<221> SITE
<222> 7..7
<223> beranched position bearing: (repeat residues 1-6)-

<220> 
<221> SITE
<222> 8..8
<223> beranched position bearing: (repeat residues 1-6)2-Lys-

<220> 
<221> SITE
<222> 9..9
<223> bAla

<400> 17
Glu Arg Asn Gly His Xaa Lys Lys Xaa 
1               5                   

<210> 18
<211> 5
<212> PRT
<213> Artificial Sequence

<220> 
<221> MOD_RES
<222> 1..1
<223> ACETYLATION

<220> 
<221> CARBOHYD
<222> 1..1
<223> Glc

<220> 
<221> REPEAT
<222> 1..2
<223> sequence repeated at branched positions 3 and 4

<220> 
<223> synthetic branched tetrameric glycopeptide

<220> 
<221> SITE
<222> 2..2
<223> bAla

<220> 
<221> SITE
<222> 3..3
<223> branched postion bearing: (repeat residues 1-2)-

<220> 
<221> SITE
<222> 4..4
<223> branched postion bearing: (repeat residues 1-2)2-Lys-

<220> 
<221> SITE
<222> 5..5
<223> bAla

<400> 18
Asn Xaa Lys Lys Xaa 
1               5   

<210> 19
<211> 9
<212> PRT
<213> Artificial Sequence

<220> 
<221> MOD_RES
<222> 1..1
<223> ACETYLATION

<220> 
<221> REPEAT
<222> 1..6
<223> sequence repeated at brancehd positions 7 and 8

<220> 
<223> synthetic branched tetrameric glycopeptide

<220> 
<221> CARBOHYD
<222> 3..3
<223> Glc

<220> 
<221> SITE
<222> 7..7
<223> branched position bearing: (repeat residues 1-6)-

<220> 
<221> SITE
<222> 8..8
<223> branched position bearing: (repeat residues 1-6)2-Lys-

<220> 
<221> SITE
<222> 9..9
<223> bAla

<400> 19
Glu Arg Asn Gly His Ser Lys Lys Xaa 
1               5                   

